1. Home
  2. PRSO vs CMMB Comparison

PRSO vs CMMB Comparison

Compare PRSO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRSO

Peraso Inc.

HOLD

Current Price

$0.91

Market Cap

14.4M

Sector

Technology

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.52

Market Cap

13.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
CMMB
Founded
2008
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4M
13.0M
IPO Year
2000
2023

Fundamental Metrics

Financial Performance
Metric
PRSO
CMMB
Price
$0.91
$1.52
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$3.00
$25.00
AVG Volume (30 Days)
624.2K
49.9K
Earning Date
05-11-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
81.23
101.67
EPS
N/A
0.04
Revenue
$14,573,000.00
N/A
Revenue This Year
$18.48
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
$38.00
Revenue Growth
5.99
N/A
52 Week Low
$0.77
$0.87
52 Week High
$2.37
$3.86

Technical Indicators

Market Signals
Indicator
PRSO
CMMB
Relative Strength Index (RSI) 42.23 39.66
Support Level $0.81 $1.48
Resistance Level $0.95 $1.89
Average True Range (ATR) 0.06 0.17
MACD -0.02 -0.04
Stochastic Oscillator 9.86 4.60

Price Performance

Historical Comparison
PRSO
CMMB

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: